Zurück zur Übersicht
| Cancers. 2022 Feb 10. pii: cancers14040887. doi: 10.3390/cancers14040887 |
| Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis. |
| Del Giudice F1, Flammia RS2, Chung BI3, Moschini M4, Pradere B5, Mari A6, Soria F7, Albisinni S8, Krajewski W9, Szydełko T10, Laukhtina E11, D'Andrea D12, Gallioli A13, Mertens LS14, Maggi M15, Sciarra A16, Salciccia S17, Ferro M18, Scornajenghi CM19, Asero V20, Cattarino S21, De Angelis M22, Cacciamani GE23, Autorino R24, Pandolfo SD25, Falagario UG26, D'Altilia N27, Mancini V28, Chirico M29, Cinelli F30, Bettocchi C31, Cormio L32, Carrieri G33, De Berardinis E34, Busetto GM35, On Behalf Of European Association Of Urology Eau-Young Academic Urologists Yau Urothelial Cancer Working Party |
 Author information
|
|
Abstract BACKGROUND: Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) is the standard therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The superiority of any BCG strain over another could not be demonstrated yet. METHODS: Patients with NMIBCs underwent adjuvant induction ± maintenance schedule of intravesical immunotherapy with either BCG TICE or RIVM at two high-volume tertiary institutions. Only BCG-naïve patients and those treated with the same strain over the course of follow-up were included. One-to-one (1:1) propensity score matching (PSM) between the two cohorts was utilized to adjust for baseline demographic and tumor characteristics imbalances. Kaplan-Meier estimates and multivariable Cox regression models according to high-risk NMIBC prognostic factors were implemented to address survival differences between the strains. Sub-group analysis modeling of the influence of routine secondary resection (re-TUR) in the setting of the sole maintenance adjuvant schedule for the two strains was further performed. RESULTS: 852 Ta-T1 NMIBCs ( = 719, 84.4% on TICE; = 133, 15.6% on RIVM) with a median of 53 (24-77) months of follow-up were reviewed. After PSM, no differences at 5-years RFS, PFS, and CSS at both Kaplan-Meier and Cox regression analyses were detected for the whole cohort. In the sub-group setting of full adherence to European/American Urology Guidelines (EAU/NCCN), BCG TICE demonstrated longer 5-years RFS compared to RIVM (68% vs. 43%, = 0.008; HR: 0.45 95% CI 0.25-0.81). CONCLUSION: When routinely performing re-TUR followed by a maintenance BCG schedule, TICE was superior to RIVM for RFS outcomes. However, no significant differences were detected for PFS and CSS, respectively. |
|
KEYWORDS: BCG strain, BCG-RIVM, BCG-TICE, bladder cancer, cancer-specific survival, progression-free survival, re-TUR, recurrence-free survival |
|
Publikations ID: 35205635 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
